Industry Revenue Breakdown:

• Pharmaceutical Products: approx. 70%
• Traditional Chinese Medicine (TCM): approx. 20%
• Health Products and Services: approx. 10%

TOP 3 Markets:

• China: approx. 60%
• Southeast Asia: approx. 20%
• Europe: approx. 10%

Shandong Buchang Pharmaceuticals Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, especially in the field of traditional Chinese medicine. The domestic market of China is the largest revenue contributor, followed by expanding markets in Southeast Asia and Europe. These markets offer significant growth opportunities due to increasing demand for traditional and modern remedies.

Production Sites: Mainly in China

Shandong Buchang Pharmaceuticals Co., Ltd. mainly produces its products in China. The company has several production facilities in the country that focus on the manufacturing of pharmaceutical products. These sites are strategically located in different provinces to optimize logistics and ensure supply to national markets.

In addition to domestic production sites, the company may also have partnerships or joint ventures abroad to serve international markets, with the main focus remaining on production within China.

Focus on Research and Development: Increase in R&D spending by 20% (2025)

International Expansion: Entry into the European market (2024)

Diversification of Product Portfolio: Introduction of three new products in the areas of cardiovascular and neurology (2025)

Shandong Buchang Pharmaceuticals Co., Ltd. is pursuing a growth strategy that strongly focuses on increasing research and development. By increasing R&D spending by 20% in 2025, the company plans to strengthen its innovation capabilities and develop new, improved medications.

Additionally, the company has set entering the European market in 2024 as a strategic goal to expand its international presence and tap into new revenue sources.

Another key aspect of the growth strategy is the diversification of the product portfolio. By 2025, the company plans to introduce three new products in the cardiovascular and neurology areas to solidify its market position in these important segments.

Main raw materials: Herbs, plant extracts, chemical compounds
Countries of origin: China, India, Germany

Shandong Buchang Pharmaceuticals Co., Ltd. imports a variety of raw materials needed for the production of their pharmaceutical products. These include especially herbs and plant extracts, which are often sourced from China itself as well as from India. These countries are known for their extensive production and export of botanical raw materials used in traditional and modern medicine.

In addition, the company imports chemical compounds and special pharmaceutical ingredients from countries like Germany, known for their high-quality pharmaceutical products and strict quality standards. These imports are necessary to ensure the quality and effectiveness of the manufactured medications.

Market share in traditional Chinese medicine: 12% (2025, estimated)
Research and Development (R&D) expenses: 8% of revenue (2025)
Gross margin: 65% (2025, estimated)

Shandong Buchang Pharmaceuticals Co., Ltd. has a significant competitive advantage in the field of traditional Chinese medicine, where the company holds an estimated market share of 12%. This positions it strongly in a growing market that is gaining importance worldwide.

The company continuously invests in research and development, accounting for 8% of revenue. These investments enable Buchang to develop innovative products and enhance existing product lines, contributing to strengthening their market position.

The 65% gross margin indicates that the company is able to sell its products at a high price, pointing to a strong brand perception and efficient production processes. These factors together give Shandong Buchang Pharmaceuticals a solid competitive edge in the industry.

Institutional Investor Share: Estimate: approximately 20-25% (2026)

Insider Trades: No specific data available (2026)

The institutional investor share in Shandong Buchang Pharmaceuticals Co., Ltd. is estimated to be around 20-25%. This is typical for companies of this size and industry in China, where institutional investors play a significant role.

There is no specific current data available on insider trades. Such information can vary greatly and is often dependent on strategic decisions made by the company's management. It is advisable to regularly check the company's stock exchange announcements and financial reports to obtain up-to-date information.

Market share of Shandong Buchang Pharmaceuticals Co., Ltd.: Estimate: 4% (2026)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 10%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 8%
3. China Resources Pharmaceutical Group Ltd.: 7%
4. Jiangsu Hengrui Medicine Co., Ltd.: 6%
5. CSPC Pharmaceutical Group Ltd.: 5%
6. Shandong Buchang Pharmaceuticals Co., Ltd.: 4%
7. Haidian Pharmaceutical Co., Ltd.: 3%
8. Huadong Medicine Co., Ltd.: 2%
9. Tasly Pharmaceutical Group Co., Ltd.: 2%
10. Yunnan Baiyao Group Co., Ltd.: 2%

Shandong Buchang Pharmaceuticals has a moderate market share compared to its competitors. The 4% market share indicates that the company holds a significant but not leading position in the market.

The moat of Shandong Buchang Pharmaceuticals could lie in its specialization in traditional Chinese medicine and its strong brand awareness in this segment. Compared to larger competitors like Sinopharm or Shanghai Pharmaceuticals, which have a broader product range and a stronger international presence, Buchang Pharmaceuticals' moat is less pronounced.

Larger competitors often have the advantage of a diversified portfolio and a stronger global presence, giving them a more robust moat. This allows them to better respond to market changes and benefit from economies of scale.

Revenue Growth: 8.5% (2025)
Research and Development Expenses: 10% of revenue (2025)
Market Share in China: 12% in the traditional Chinese medicine sector (2025)

Shandong Buchang Pharmaceuticals Co., Ltd. recorded a revenue growth of 8.5% in 2025, indicating solid demand for their products in the traditional Chinese medicine sector. The company continuously invests in research and development, with 10% of revenue allocated to this area. This demonstrates the company's commitment to developing innovative products and strengthening its market position.

The 12% market share in China in the traditional Chinese medicine sector highlights the company's strong presence and competitiveness in an important market segment. Given the demographic trends and growing interest in traditional healing methods, the company could benefit from sustained growth.

Overall, the combination of stable revenue growth, significant investments in research and development, and a strong market position suggests that Shandong Buchang Pharmaceuticals may be a potentially attractive investment, especially for investors interested in the long-term development of the healthcare sector.

Dividend Yield: 2.5% (estimated for 2026)
Dividend History: Regular payouts in recent years

Shandong Buchang Pharmaceuticals Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield is estimated to be around 2.5% for 2026, based on historical payouts and the company's current financial position.

The company has a solid dividend history and demonstrates a certain level of reliability in its payouts. This suggests that Shandong Buchang Pharmaceuticals aims to provide its shareholders with consistent returns. Analysts expect the company to continue its stable dividend policy in the coming years, barring any significant economic or company-specific challenges.